HWM
CPRX

Hohimer Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Hohimer Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$272K Sell
10,995
-5,436
-33% -$130K 0.03% 246
2025
Q4 		$384K Buy
16,431
+18
+0.1% +$401 0.05% 202
2025
Q3 		$323K Buy
16,413
+4,439
+37% +$91.3K 0.05% 214
2025
Q2 		$260K Sell
11,974
-6,096
-34% -$144K 0.05% 197
2025
Q1 		$438K Buy
18,070
+629
+4% +$14.2K 0.09% 170
2024
Q4 		$364K Buy
17,441
+898
+5% +$19.3K 0.07% 163
2024
Q3 		$329K Buy
+16,543
New +$307K 0.07% 161

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Hohimer Wealth Management's CPRX Position: Q1 2026 in Review

Hohimer Wealth Management reduced its Catalyst Pharmaceutical (CPRX) stake by 33% in Q1 2026, selling an estimated $130K and leaving 10,995 shares worth $272K. The position accounts for 0.03% of the portfolio, ranked #246.

Hohimer Wealth Management first reported a position in CPRX in Q3 2024 and has held it in 7 quarters since. The position peaked at $438K in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Hohimer Wealth Management held 10,995 shares of Catalyst Pharmaceutical worth $272K as of Q1 2026.
  • Hohimer Wealth Management sold 5,436 Catalyst Pharmaceutical shares in Q1 2026, an estimated $130K.
  • Catalyst Pharmaceutical made up 0.03% of Hohimer Wealth Management's portfolio in Q1 2026, its #246 holding.
  • Hohimer Wealth Management first reported a position in Catalyst Pharmaceutical in Q3 2024 and has held it in 7 quarters since.
  • Hohimer Wealth Management's Catalyst Pharmaceutical position peaked at $438K in Q1 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Hohimer Wealth Management's 13F filing for Q1 2026, filed 1 May 2026.